You are here


A SNP-based blood test for predicting breast cancer survival and determining treatment strategies

A SNP-based blood test for predicting breast cancer survival and determining treatment strategies

The NCI seeks licensing of methods that provide significant improvements in examining additional SNPs for improved prognostics and to evaluate whether the SNP signature is associated with overall cancer incidence or effective treatment strategies.
NIH Reference Number
Product Type
  • precision medicine, SNP, single nucleotide polymorphism, gDNA
Collaboration Opportunity
This invention is available for licensing and co-development.
Description of Technology

Metastasis is a primary cause of patient morbidity and mortality in solid tumors. Although recent advances in genomic technologies have provided major insights into tumor etiology, there is a significant lack of knowledge regarding the factors that contribute to metastasis.

Through studying the metastatic susceptibility of tumors, NCI researchers discovered a select panel of single nucleotide polymorphisms (SNPs) and a method for predicting breast cancer patient’s survival. In this array, SNPs are analyzed from a patient’s genomic DNA (gDNA). The results can be used to predict whether a patient is likely to respond to current breast cancer treatment strategies. This technology can indicate the probability of responding to treatment and can also identify those patients that require alternative, more aggressive therapeutic strategies.

Importantly, this invention has several advantages over the currently-offered gene expression-based breast cancer prognostic tests. Since this array can be completed following routine blood draw, rather than through a tumor biopsy, the samples are more stable, the process is quicker, simpler, less-invasive, and more cost-effective than current methods.

Potential Commercial Applications
  • Identification of patients with higher susceptibility to tumor progression (i.e., metastasis).
  • Prediction of breast cancer survival (less than 10 years, for example) using a new array and methods.
Competitive Advantages
  • Since the array processes DNA from blood rather than tissue from a standard biopsy or resection of a primary tumor, it is faster, simpler, more cost-efficient, less-invasive, and more stable because gDNA is more stable than tumor mRNA

Kent W. Hunter, Howard H. Yang PhD, Maxwell P. Lee PhD

Development Stage
Patent Status
  • U.S. Provisional: U.S. Provisional Patent Application Number 62/297,557, Filed 19 Feb 2016
Therapeutic Area
Monday, June 18, 2018